137.05 USD
-1.17
0.85%
At close Apr 30, 4:00 PM EDT
After hours
137.10
+0.05
0.04%
1 day
-0.85%
5 days
2.54%
1 month
-0.82%
3 months
-25.04%
6 months
-41.74%
Year to date
-23.46%
1 year
-34.35%
5 years
-59.14%
10 years
11.46%
 

About: Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Employees: 14,100

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

74% more call options, than puts

Call options by funds: $4.11M | Put options by funds: $2.37M

4.64% more ownership

Funds ownership: 94.43% [Q3] → 99.07% (+4.64%) [Q4]

5% less first-time investments, than exits

New positions opened: 87 | Existing positions closed: 92

9% less repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 187

3% less funds holding

Funds holding: 520 [Q3] → 505 (-15) [Q4]

26% less capital invested

Capital invested by funds: $11B [Q3] → $8.19B (-$2.81B) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$140
2%
upside
Avg. target
$151
10%
upside
High target
$191
39%
upside

5 analyst ratings

positive
20%
neutral
60%
negative
20%
Truist Securities
Richard Newitter
57% 1-year accuracy
29 / 51 met price target
2%upside
$140
Hold
Maintained
11 Apr 2025
Morgan Stanley
Patrick Wood
50% 1-year accuracy
6 / 12 met price target
39%upside
$191
Overweight
Maintained
5 Mar 2025
B of A Securities
Craig Bijou
60% 1-year accuracy
6 / 10 met price target
2%upside
$140
Underperform
Downgraded
4 Mar 2025
Wells Fargo
Larry Biegelsen
27% 1-year accuracy
12 / 44 met price target
7%upside
$146
Equal-Weight
Maintained
28 Feb 2025
Piper Sandler
Matt O'Brien
46% 1-year accuracy
23 / 50 met price target
2%upside
$140
Neutral
Downgraded
28 Feb 2025

Financial journalist opinion

Based on 29 articles about TFX published over the past 30 days

Neutral
Business Wire
12 hours ago
TFX Investors Have Opportunity to Join Teleflex Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--TFX Investors Have Opportunity to Join Teleflex Incorporated Fraud Investigation with the Schall Law Firm.
TFX Investors Have Opportunity to Join Teleflex Incorporated Fraud Investigation with the Schall Law Firm
Neutral
Accesswire
16 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Teleflex Incorporated (TFX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Teleflex Incorporated ("Teleflex" or "the Company") (NYSE:TFX). Investors who purchased Teleflex securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TFX.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Teleflex Incorporated (TFX) And Encourages Stockholders to Connect
Neutral
GlobeNewsWire
20 hours ago
Teleflex to Present at the BofA Securities 2025 Health Care Conference
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the BofA Securities 2025 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. (PT).
Teleflex to Present at the BofA Securities 2025 Health Care Conference
Neutral
GlobeNewsWire
20 hours ago
Teleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the QuikClot Control+™ Hemostatic Device to include all grades of internal and external bleeding. The QuikClot Control+™ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical wounds, mild and moderate bleeding in cardiac surgical procedures, and bone surfaces following sternotomy.
Teleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device
Neutral
Business Wire
1 day ago
Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation – TFX
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public. So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation – TFX
Neutral
GlobeNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Negative
Zacks Investment Research
6 days ago
Earnings Preview: Teleflex (TFX) Q1 Earnings Expected to Decline
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Teleflex (TFX) Q1 Earnings Expected to Decline
Neutral
Accesswire
6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Neutral
GlobeNewsWire
6 days ago
Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting
Experienced Urologists to Present Latest Findings and Host Multiple Educational Sessions Experienced Urologists to Present Latest Findings and Host Multiple Educational Sessions
Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Charts implemented using Lightweight Charts™